PL2663564T3 - Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor - Google Patents

Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor

Info

Publication number
PL2663564T3
PL2663564T3 PL12701207T PL12701207T PL2663564T3 PL 2663564 T3 PL2663564 T3 PL 2663564T3 PL 12701207 T PL12701207 T PL 12701207T PL 12701207 T PL12701207 T PL 12701207T PL 2663564 T3 PL2663564 T3 PL 2663564T3
Authority
PL
Poland
Prior art keywords
quinolin
imidazo
kinase
compound
dual inhibitor
Prior art date
Application number
PL12701207T
Other languages
English (en)
Inventor
David Anthony Barda
Mary Margaret Mader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL2663564T3 publication Critical patent/PL2663564T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12701207T 2011-01-14 2012-01-11 Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor PL2663564T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14
PCT/US2012/020897 WO2012097039A1 (en) 2011-01-14 2012-01-11 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
EP12701207.8A EP2663564B1 (en) 2011-01-14 2012-01-11 Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor

Publications (1)

Publication Number Publication Date
PL2663564T3 true PL2663564T3 (pl) 2015-05-29

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12701207T PL2663564T3 (pl) 2011-01-14 2012-01-11 Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor

Country Status (39)

Country Link
US (2) US8440829B2 (pl)
EP (1) EP2663564B1 (pl)
JP (1) JP5891247B2 (pl)
KR (1) KR101561360B1 (pl)
CN (1) CN103282364B (pl)
AR (1) AR084551A1 (pl)
AU (1) AU2012205619B2 (pl)
BR (1) BR112013017672A2 (pl)
CA (1) CA2824760C (pl)
CL (1) CL2013002005A1 (pl)
CO (1) CO6731133A2 (pl)
CR (1) CR20130289A (pl)
CY (1) CY1116007T1 (pl)
DK (1) DK2663564T3 (pl)
DO (1) DOP2013000158A (pl)
EA (1) EA022163B1 (pl)
EC (1) ECSP13012764A (pl)
ES (1) ES2531891T3 (pl)
GT (1) GT201300180A (pl)
HR (1) HRP20150135T1 (pl)
HU (1) HUE024426T2 (pl)
IL (1) IL227165A (pl)
JO (1) JO3003B1 (pl)
ME (1) ME02019B (pl)
MX (1) MX2013008185A (pl)
MY (1) MY164705A (pl)
PE (1) PE20140864A1 (pl)
PH (1) PH12013501493A1 (pl)
PL (1) PL2663564T3 (pl)
PT (1) PT2663564E (pl)
RS (1) RS53828B1 (pl)
SG (1) SG191744A1 (pl)
SI (1) SI2663564T1 (pl)
SV (1) SV2013004496A (pl)
TN (1) TN2013000237A1 (pl)
TW (1) TWI518086B (pl)
UA (1) UA109921C2 (pl)
WO (1) WO2012097039A1 (pl)
ZA (1) ZA201304757B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
AU2016370297A1 (en) 2015-12-15 2018-05-24 Eli Lilly And Company Combination therapy for cancer
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
MX380780B (es) * 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
AU2017249078B2 (en) 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
JP7669473B2 (ja) * 2020-09-21 2025-04-28 ウェイ ジョン 血液脳関門透過能力を有する置換1-(3,3-ジフルオロピペリジン-4-イル)-イミダゾ[4,5-c]キノリン-2-オン化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換1h−イミダゾキノリン及び方法
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
JP5591809B2 (ja) * 2008-09-30 2014-09-17 ファイザー・インク イミダゾ[1,5]ナフチリジン化合物、その医薬への使用、および組成物
CN102574845B (zh) 2009-06-04 2015-09-02 诺华股份有限公司 1H-咪唑并[4,5-c]喹啉酮衍生物
CN102803259A (zh) 2009-06-04 2012-11-28 诺瓦提斯公司 用于治疗增殖性疾病的1H-咪唑并[4,5-c]喹啉酮化合物
WO2011001212A1 (en) * 2009-06-30 2011-01-06 Piramal Life Sciences Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
CA2819955A1 (en) * 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
HK1188454A1 (en) 2014-05-02
SI2663564T1 (sl) 2015-01-30
JO3003B1 (ar) 2016-09-05
PH12013501493A1 (en) 2021-06-02
NZ611541A (en) 2015-02-27
KR101561360B1 (ko) 2015-10-16
SG191744A1 (en) 2013-08-30
HRP20150135T1 (xx) 2015-03-13
ZA201304757B (en) 2014-12-23
EA201390823A1 (ru) 2013-12-30
IL227165A (en) 2016-06-30
CL2013002005A1 (es) 2013-12-27
US20120184577A1 (en) 2012-07-19
MX2013008185A (es) 2013-08-21
AU2012205619A1 (en) 2013-06-27
RS53828B1 (sr) 2015-06-30
DOP2013000158A (es) 2013-11-30
PE20140864A1 (es) 2014-07-19
SV2013004496A (es) 2017-11-07
CY1116007T1 (el) 2017-01-25
WO2012097039A1 (en) 2012-07-19
ME02019B (me) 2015-05-20
BR112013017672A2 (pt) 2018-09-18
US8658668B2 (en) 2014-02-25
JP5891247B2 (ja) 2016-03-22
ES2531891T3 (es) 2015-03-20
EP2663564B1 (en) 2014-12-17
JP2014502638A (ja) 2014-02-03
TW201307343A (zh) 2013-02-16
CR20130289A (es) 2013-10-07
US20130237562A1 (en) 2013-09-12
CN103282364B (zh) 2015-06-17
CA2824760C (en) 2016-03-15
AU2012205619B2 (en) 2015-05-21
CA2824760A1 (en) 2012-07-19
EP2663564A1 (en) 2013-11-20
GT201300180A (es) 2014-04-08
US8440829B2 (en) 2013-05-14
EA022163B1 (ru) 2015-11-30
TN2013000237A1 (en) 2014-11-10
AR084551A1 (es) 2013-05-22
KR20130116302A (ko) 2013-10-23
CO6731133A2 (es) 2013-08-15
HUE024426T2 (en) 2016-01-28
UA109921C2 (uk) 2015-10-26
DK2663564T3 (en) 2015-01-12
TWI518086B (zh) 2016-01-21
CN103282364A (zh) 2013-09-04
MY164705A (en) 2018-01-30
ECSP13012764A (es) 2013-09-30
PT2663564E (pt) 2015-02-24

Similar Documents

Publication Publication Date Title
PL2663564T3 (pl) Związek imidazo[4,5-c]chinolin-2-onu i jego zastosowanie jako podwójnego inhibitora kinazy pi3/mtor
ME03034B (me) Jedinjenja [1 ,2 ,4]triazol0[1 ,5-c]hinazol/n-5-amina supstiтuisana sa heterobiciklo pogodna za lečenje ili prevenciju poremećaja centralnog nervnog sistema
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PT2857404T (pt) Derivados de imidazo[1,2-b]piridazina como inibidores da cinase
AU2008228964A8 (en) Pyrazolopyrimidine Analogs and their use as mTOR kinase and PI3 kinase inhibitors
PT2624696T (pt) Derivados de benzimidazole como inibidores da cinase pi3
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
IL229993A0 (en) A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
EP2651937B8 (en) Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
HK1176060A (en) Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors